A phase 1/2 trial was conducted evaluating the combination of Pembrolizumab and allogeneic NK cells as compared with Pembrolizumab monotherapy in patients with recurrent stage IIIB or IV PDL1 ≥ 1% NSCLC [243]. The gene discussed is CD274; the disease is non-small cell lung carcinoma.